Stroke often leaves behind cognitive deficits that standard rehabilitation struggles to fix. Cerebrolysin, a peptide mixture derived from pig brain, has been studied for decades in post-stroke recovery. It may improve memory, attention, and executive function. But the clinical evidence is mixed. Some trials show clear benefits. Others are less impressive. This article examines the data and explores a potential synergy with NAD+.
What the Cerebrolysin Clinical Literature Shows
Cerebrolysin contains neurotrophic factors that mimic the brain's own growth signals. In animal models, it promotes neurogenesis and synaptic plasticity. Human studies have tested it in ischemic stroke. A 2016 meta-analysis of nine randomized controlled trials found significant cognitive improvements at 30 and 90 days post-treatment. The effect was most pronounced in patients with moderate to severe deficits.
One trial used 30 mL daily for 10 days, then 10 mL twice weekly for 8 weeks. Patients on Cerebrolysin scored better on the Mini-Mental State Exam (MMSE) and the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog). But not all studies agree. A 2018 trial showed no difference versus placebo on the primary endpoint. The authors noted that the placebo group had unusually high recovery rates. This suggests that patient selection matters. Cerebrolysin may work best when started early and given at adequate doses.
- Typical protocol: 10-30 mL/day IV for 10-21 days, followed by maintenance doses.
- Most trials use the intravenous route. Intramuscular administration exists but has less evidence.
- Side effects are generally mild: headache, dizziness, injection site reactions.
For a deeper look at how peptide-based nootropics compare, see this analysis of Dihexa's neuroprotective mechanisms versus other peptides.
NAD+ in the Post-Stroke Brain
NAD+ is a coenzyme critical for energy metabolism and DNA repair. After a stroke, NAD+ levels drop sharply. This impairs mitochondrial function and worsens neuronal damage. Restoring NAD+ could support recovery. Preclinical studies show that NAD+ precursors like nicotinamide riboside reduce infarct size and improve motor function.
But cognitive outcomes are less studied. One mouse study found that NAD+ supplementation after traumatic brain injury preserved spatial memory. The mechanism likely involves sirtuins, a class of proteins that depend on NAD+. Sirtuins regulate inflammation and oxidative stress. Both are key drivers of post-stroke cognitive decline.
Human trials are limited. A small pilot study gave nicotinamide riboside to stroke survivors for 6 weeks. Participants showed trends toward better processing speed. But the study was underpowered. Larger trials are needed. Still, the rationale for combining NAD+ with Cerebrolysin is strong. Cerebrolysin provides growth signals. NAD+ provides the energy to act on them.
Why Combine Cerebrolysin and NAD+?
The two compounds target different but complementary pathways. Cerebrolysin stimulates neurogenesis and synaptic repair. NAD+ supports the metabolic demands of those processes. Without sufficient NAD+, newly formed neurons may not function optimally. This could explain why some patients respond poorly to Cerebrolysin alone.
Consider the timeline. In the acute phase, NAD+ could limit initial damage. Cerebrolysin could then enhance remodeling in the subacute and chronic phases. No clinical trials have tested this combination yet. But biohackers often stack them. Anecdotal reports describe faster cognitive gains. These reports are uncontrolled. They should be interpreted with caution.
Statements about mechanism describe pathways reported in published animal and in vitro work. Human evidence varies.
Other Nootropics That Fit the Picture
Several other compounds appear in post-stroke recovery protocols. Semax, a synthetic peptide, has been studied in Russia for stroke. It may improve attention and memory. Dihexa, a small molecule, is far more potent than BDNF in promoting synaptic connections. But human data is almost nonexistent. MOTS-c, a mitochondrial peptide, could complement NAD+ by improving energy efficiency. Selank, an anxiolytic peptide, might reduce post-stroke anxiety that interferes with cognition.
None of these have the clinical track record of Cerebrolysin. But they illustrate a broader principle. Post-stroke recovery likely requires a multi-target approach. The brain's repair systems are complex. Single agents rarely address all deficits.
- Semax: 0.1% nasal drops, 2-3 times daily. Some evidence for cognitive enhancement in stroke.
- Dihexa: Oral or topical. Potent synaptogenic effects in animals. Human safety data is sparse.
- MOTS-c: Injectable peptide. Improves glucose metabolism and may protect neurons.
- Selank: Nasal spray or injection. Reduces anxiety without sedation. May indirectly aid cognition.
For a detailed comparison of Dihexa's mechanism with other nootropic peptides, refer back to the earlier discussion on Dihexa and neuroprotection.
Practical Considerations and Dosing
Cerebrolysin requires intravenous access. This limits home use. Some clinics offer IV infusions. Others teach patients to self-administer. The standard dose is 10-30 mL per day. Treatment cycles often last 4 weeks. Maintenance can be 5 mL twice weekly.
NAD+ can be taken orally as nicotinamide riboside or NMN. Typical doses are 250-500 mg per day. Intravenous NAD+ is also available. It delivers higher peak levels. But it is expensive and time-consuming. Combining oral NAD+ precursors with IV Cerebrolysin is a practical stack.
Timing matters. Some users take NAD+ in the morning for energy. Cerebrolysin is often administered in the morning as well. No known interactions exist. But both can cause flushing or headache. Starting with low doses is wise.
Where the Evidence Is Strongest
Cerebrolysin has the most data in subacute ischemic stroke. Trials in hemorrhagic stroke are fewer. Cognitive outcomes are usually secondary endpoints. This makes it hard to isolate the effect on cognition. Future studies should use detailed neuropsychological batteries.
NAD+ research is booming. But it focuses on aging and neurodegeneration. Stroke-specific trials are rare. The combination approach is purely theoretical for now. Animal studies are needed to test synergy. Then human pilot trials can follow.
If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.
Monitoring Your Progress
Objective tracking is essential. Cognitive tests like the Montreal Cognitive Assessment (MoCA) can be done at home. Repeat testing every few months. Keep a journal of daily function. Note any improvements in memory, focus, or problem-solving.
Biomarkers may help. NAD+ levels can be measured in blood. But this is not routine. Some labs offer it. Tracking changes could guide dosing. For Cerebrolysin, no standard biomarker exists. Clinical response remains the best guide.
- Use the MoCA or MMSE for cognitive screening.
- Track activities of daily living (ADLs) for functional gains.
- Consider a continuous performance test for attention.
- Monitor mood with a validated scale like the PHQ-9.
Risks and Unknowns
Cerebrolysin is generally safe. But it is derived from animal tissue. Allergic reactions are possible. Rare cases of seizures have been reported. The risk is low. Still, it should be used under medical supervision.
NAD+ precursors are well-tolerated. High doses can cause nausea or liver stress. Long-term safety data is lacking. The combination has no known risks. But polypharmacy always increases uncertainty. Caution is advised.
The biggest unknown is efficacy. Cerebrolysin works for some, not others. NAD+ may tip the balance. Or it may add nothing. Only controlled trials can answer this. Until then, patients and clinicians must weigh the limited evidence against the potential for meaningful recovery.